RxDoctor Payments DataLook up a doctor →

Mary Hughes, MD

Surgical Oncology · Ashland, KYNPI 1326339573

Payments from drug & device makers

$5,301in general payments, 2019–2025

Across 272 payments — averaging $19.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$645
  • Novartis$570
  • Amgen$393
  • Daiichi Sankyo Inc.$297
  • Incyte Corporation$281
  • Shield Therapeutics Inc$249
  • plus $3K from 52 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merck34$645
Novartis26$570
Amgen25$393
Daiichi Sankyo Inc.18$297
Incyte Corporation15$281
Shield Therapeutics Inc3$249
Bristol Myers Squibb13$248
Johnson & Johnson(2 entities)13$246
AstraZeneca(2 entities)11$219
Seagen Inc.10$168
Pharmacosmos Therapeutics Inc.7$130
AbbVie7$128
GSK5$117
Coherus Oncology, Inc.5$100
Genmab U.S., Inc.4$95
Tersera Therapeutics LLC4$94
Takeda Pharmaceuticals U.S.A., Inc.5$84
Puma Biotechnology, Inc.5$80
Karyopharm Therapeutics Inc.3$63
Jazz Pharmaceuticals Inc.4$50
Celltrion USA Inc.2$49
Novocure Inc.4$49
Agios Pharmaceuticals, Inc.3$47
Livanova USA, Inc.1$45
Argenx US, Inc.2$42
Stemline Therapeutics Inc.2$42
Regeneron Healthcare Solutions, Inc.2$41
AMAG Pharmaceuticals, Inc.3$39
Eisai Inc.2$37
Foundation Medicine, Inc.2$33
Tactile Systems Technology Inc1$33
Vertex1$31
Kyowa Kirin, Inc.2$30
Bayer2$29
Inspire Medical Systems, Inc.1$29
Sobi, Inc1$26
Genentech USA, Inc.2$26
Azurity Pharmaceuticals, Inc.1$26
Astellas Pharma US Inc1$25
Dova Pharmaceuticals2$25
Hologic Sales And Service, LLC1$24
Boehringer Ingelheim1$23
Ipsen Biopharmaceuticals, Inc1$23
Myriad Genetic Laboratories, Inc.1$22
Recordati_rare_diseases_inc.1$22
Verastem, Inc.1$21
Sun Pharmaceutical Industries Inc.1$21
Caris MPI, Inc.1$20
ADC Therapeutics America, Inc.1$20
Pharmaessentia USA Corporation1$19
Sanofi1$18
EMD Serono, Inc.1$17
Morphosys, US Inc.1$17
Spectrum Pharmaceuticals Inc.1$16
Viiv Healthcare Company1$15
Clovis Oncology, Inc.1$14
Rigel Pharmaceuticals, Inc.1$14
Aurobindo Pharma USA, Inc.1$11

How this compares

$5,301 in reported general payments places this provider in the 75th percentile of 29 surgical oncology providers in Kentucky.

See all surgical oncology providers in Kentucky →

Medicare billing

Part B allowed, 2024
$45,675
Medicare patients
136
Services billed
275

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other surgical oncology in Ashland

See the full list for Kentucky →

Where these figures come from

Is this you, or does something look wrong? →